How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/teriflunomide-oral-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Teriflunomide Oral Tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Teriflunomide Oral Tablet (Teriflunomide Oral Tablet) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant; dihydroorotate dehydrogenase inhibitor. Area: Immunology; Neurology.

phase 3 Immunosuppressant; dihydroorotate dehydrogenase inhibitor Dihydroorotate dehydrogenase (DHODH) Immunology; Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Teriflunomide Oral Tablet (Teriflunomide Oral Tablet) — Oslo University Hospital. Teriflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby reducing proliferation of activated lymphocytes.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Teriflunomide Oral Tablet TARGET	Teriflunomide Oral Tablet	Oslo University Hospital	phase 3	Immunosuppressant; dihydroorotate dehydrogenase inhibitor	Dihydroorotate dehydrogenase (DHODH)
Teriflunomide HMR1726	Teriflunomide HMR1726	Sanofi	marketed	Dihydroorotate dehydrogenase inhibitor; immunosuppressant	Dihydroorotate dehydrogenase (DHODH)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant; dihydroorotate dehydrogenase inhibitor class)

Oslo University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Teriflunomide Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/teriflunomide-oral-tablet. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab